Cargando…
Have Therapeutics Enhanced Our Knowledge of Axial Spondyloarthritis?
PURPOSE OF REVIEW: An overview of how the treatment landscape of axial spondyloarthritis (axSpA) has shaped our understanding of the disease. RECENT FINDINGS: Prior to the millennium, non-steroidal anti-inflammatory drugs (NSAIDs) were the only treatment for axSpA, yet only 30% of patients responded...
Autores principales: | Harrison, S. R., Marzo-Ortega, H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9958165/ https://www.ncbi.nlm.nih.gov/pubmed/36652160 http://dx.doi.org/10.1007/s11926-023-01097-7 |
Ejemplares similares
-
Correction to: Have Therapeutics Enhanced Our Knowledge of Axial Spondyloarthritis?
por: Harrison, S. R., et al.
Publicado: (2023) -
Axial spondyloarthritis: coming of age
por: Marzo-Ortega, Helena
Publicado: (2020) -
Defining the target: clinical aims in axial spondyloarthritis
por: Marzo-Ortega, Helena, et al.
Publicado: (2018) -
Novel Therapeutic Targets in Axial Spondyloarthritis
por: Worth, Claudia, et al.
Publicado: (2018) -
COVID-19 in axial spondyloarthritis care provision: helping to straighten the long and winding road
por: Marzo-Ortega, Helena, et al.
Publicado: (2021)